Horama SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Horama SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11069
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Horama SA (Horama) is a biotechnology company, which develops gene therapy products based on recombinant adeno-associated virus (rAAV) vectors for the treatment of rare ophthalmic diseases, including retinopathies and maculopathies. Its pipeline gene replacement products include HORA-RPE65, developed for the treatment of retinal dystrophy caused by RPE65 gene mutations; HORA-PDE6B, is designed for the treatment of retinitis pigmentosa (RP) caused by PDE6ß defects; HORA-RLBP1, being developed for the treatment of retinal dystrophy caused by RLBP1 mutations. The company has clinical and academic collaborations with Institute for Neurosciences of Montpellier, Reference Centers for rare ophthalmological diseases, among others. Horama is headquartered in Paris, lle-de-France, France.

Horama SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Horama SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Horama SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Horama SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Horama SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Horama SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Horama SA, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Horama Raises Additional USD4.1 Million in Series B Financing 10
Horama Raises USD22 Million in Series B Financing 12
Private Equity 14
Horama Raises USD4.4 Million in Private Equity Financing 14
Equity Offering 15
Horama Raises USD0.6 Million in Private Placement of Shares 15
Horama Spin off from Inserm Transfert 16
Horama SA – Key Competitors 17
Horama SA – Key Employees 18
Horama SA – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
May 15, 2018: HORAMA Names Dr Russell Greig As New Board Chairman 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Horama SA, Pharmaceuticals & Healthcare, Key Facts 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Horama SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Horama SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Horama SA, Deals By Therapy Area, 2012 to YTD 2018 8
Horama SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Horama Raises Additional USD4.1 Million in Series B Financing 10
Horama Raises USD22 Million in Series B Financing 12
Horama Raises USD4.4 Million in Private Equity Financing 14
Horama Raises USD0.6 Million in Private Placement of Shares 15
Horama Spin off from Inserm Transfert 16
Horama SA, Key Competitors 17
Horama SA, Key Employees 18

List of Figures
Horama SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Horama SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Horama SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Horama SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Horama SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Horama SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Savannah Petroleum Plc (SAVP):石油・ガス:M&Aディール及び事業提携情報
    Summary Savannah Petroleum Plc (Savannah Petroleum) is an oil and gas company. The company explores, appraises, develops, and produces conventional oil deposits. It operates principal assets in the R1/R2 and R3/R4 PSC areas of the Agadem Rift Basin in South East Niger. Savannah Petroleum blocks cove …
  • Himatsingka Seide Ltd:企業の戦略・SWOT・財務分析
    Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report Summary Himatsingka Seide Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • ScanSource Inc (SCSC):企業の財務・戦略的SWOT分析
    ScanSource Inc (SCSC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Willamette Valley Vineyards, Inc.:企業の戦略・SWOT・財務情報
    Willamette Valley Vineyards, Inc. - Strategy, SWOT and Corporate Finance Report Summary Willamette Valley Vineyards, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • 3i Group Plc:企業の戦略・SWOT・財務情報
    3i Group Plc - Strategy, SWOT and Corporate Finance Report Summary 3i Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Exchange Income Corporation:企業の戦略・SWOT・財務分析
    Exchange Income Corporation - Strategy, SWOT and Corporate Finance Report Summary Exchange Income Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Nymox Pharmaceutical Corp (NYMX):企業の財務・戦略的SWOT分析
    Nymox Pharmaceutical Corp (NYMX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Linamar Corporation (LNR):企業の財務・戦略的SWOT分析
    Linamar Corporation (LNR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • eLong, Inc.:企業の戦略・SWOT・財務情報
    eLong, Inc. - Strategy, SWOT and Corporate Finance Report Summary eLong, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • University of Pennsylvania:医療機器:M&Aディール及び事業提携情報
    Summary University of Pennsylvania (UOP) is an educational university that provides distance learning facilities for professional courses. The university offers courses such as art and archaeology, accounting, biochemistry, bioengineering, biomedical graduate studies, city and regional planning, cri …
  • Vestas Wind Systems AS (VWS)-エネルギー分野:企業M&A・提携分析
    Summary Vestas Wind Systems A/S (Vestas) is a renewable energy company that designs, manufactures, constructs, installs, and services wind turbines. The company partners with customers to monitor wind energy production and performance of the wind power plant throughout its lifetime. It offers soluti …
  • Montisera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Montisera Ltd (Montisera) focuses on discovering, developing and commercialising bioactive compounds and molecules for pharmaceutical and food industries. Its pipeline portfolio includes Montisera D15 1 for alcoholism; Montisera D 4 for treating lower urinary tract symptoms, Montisera D15 2 …
  • Axela Inc:製品パイプライン分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • Reliance Communications Limited:企業の戦略・SWOT・財務情報
    Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Communications Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • DIC Corporation:企業の戦略・SWOT・財務分析
    DIC Corporation - Strategy, SWOT and Corporate Finance Report Summary DIC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Nippon Suisan Kaisha, Ltd.
    Nippon Suisan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Suisan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Merit Medical Systems Inc (MMSI):企業の製品パイプライン分析2018
    Summary Merit Medical Systems, Inc. (Merit Medical) offers a wide range of single-use medical devices for interventional and diagnostic procedures. The company’s products include inflation devices and accessories, diagnostic and therapeutic catheters, diagnostic and hydrophilic products, thrombolyti …
  • 1-800-FLOWERS.COM, Inc. (FLWS):企業の財務・戦略的SWOT分析
    1-800-FLOWERS.COM, Inc. (FLWS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Helix Resources Ltd (HLX):企業の財務・戦略的SWOT分析
    Summary Helix Resources Ltd (HRL) operates as a mining and mineral exploration company. The company carries out the business of identification, acquisition, and development of mineral properties. It explores gold, copper, zinc, uranium, nickel, and iron ore properties. HRL's projects include Colleri …
  • IntriCon Corp (IIN)-医療機器分野:企業M&A・提携分析
    Summary IntriCon Corp (IntriCon) is a designer, developer and manufacturer of miniature and micro-miniature body-worn medical and electronics products. The company’s products include glucose monitoring, medical coils, cardiac monitoring, amplifiers, systems, plastic medical molding, support products …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆